Chemomab Therapeutics Ltd. SEC filings CMMB
Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| EFFECT | Filing | Oct 30, 2026 | — |
| DEFM14A | Filing | Oct 30, 2026 | — |
| S-4/A | Filing | Oct 29, 2026 | — |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| S-4/A | Filing | Oct 19, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| S-4 | Registration for a merger or exchange | Sep 25, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 9, 2026 | — |
| 4 | Insider transaction | Sep 1, 2026 | Aug 27, 2026 |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 13, 2026 | — |
| DRS | Filing | Aug 12, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 10, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jul 16, 2026 | — |
| 6-K | Current report (foreign issuer) | Jul 8, 2026 | Jul 8, 2026 |
| 3 | Initial insider ownership | Jun 3, 2026 | Jun 1, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 1, 2026 | May 29, 2026 |
| 6-K | Current report (foreign issuer) | May 14, 2026 | May 14, 2026 |
| 6-K | Current report (foreign issuer) | May 6, 2026 | May 6, 2026 |
| 6-K | Current report (foreign issuer) | Apr 28, 2026 | Apr 28, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 31, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 31, 2026 | Mar 18, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 23, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 20, 2026 | Mar 20, 2026 |
| 6-K | Current report (foreign issuer) | Mar 19, 2026 | Mar 19, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 10, 2026 | — |
| 6-K | Current report (foreign issuer) | Nov 21, 2025 | Nov 21, 2025 |
| 6-K | Current report (foreign issuer) | Aug 22, 2025 | Aug 22, 2025 |
| 6-K | Current report (foreign issuer) | Aug 14, 2025 | Jun 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 11, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 25, 2025 | Jul 25, 2025 |
| 424B5 | Prospectus supplement | Jul 25, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 1, 2025 | Jul 1, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 23, 2025 | — |
| 6-K | Current report (foreign issuer) | May 27, 2025 | May 27, 2025 |
| 6-K | Current report (foreign issuer) | May 15, 2025 | May 15, 2025 |
| 6-K | Current report (foreign issuer) | Apr 15, 2025 | Apr 15, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 10, 2025 | — |
| 20-F | Annual report (foreign issuer) | Apr 4, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 27, 2025 | Mar 27, 2025 |
| 6-K | Current report (foreign issuer) | Mar 20, 2025 | Mar 20, 2025 |
| 6-K | Current report (foreign issuer) | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Current report (foreign issuer) | Feb 19, 2025 | Feb 19, 2025 |
| EFFECT | Filing | Dec 10, 2024 | — |
| POS AM | Filing | Dec 2, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 29, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 21, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 18, 2024 |
| 424B5 | Prospectus supplement | Nov 15, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Nov 14, 2024 |
| 6-K | Current report (foreign issuer) | Oct 11, 2024 | Oct 11, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Sep 16, 2024 | — |
| 144 | Notice of proposed sale | Sep 12, 2024 | — |
| 424B3 | Prospectus | Sep 9, 2024 | — |
| EFFECT | Filing | Sep 6, 2024 | — |
| CORRESP | Letter to the SEC | Sep 4, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 23, 2024 | — |
| 6-K | Current report (foreign issuer) | Aug 21, 2024 | Jun 30, 2024 |
| SC 13G | Ownership over 5% (passive) | Aug 20, 2024 | — |
| D | Filing | Aug 9, 2024 | — |
| 6-K | Current report (foreign issuer) | Jul 25, 2024 | Jul 25, 2024 |
| 6-K | Current report (foreign issuer) | Jun 12, 2024 | Jun 12, 2024 |
| 6-K | Current report (foreign issuer) | May 9, 2024 | May 9, 2024 |
| 6-K | Current report (foreign issuer) | May 8, 2024 | May 8, 2024 |
| 6-K | Current report (foreign issuer) | May 3, 2024 | May 3, 2024 |
| 20-F | Annual report (foreign issuer) | Mar 28, 2024 | Dec 31, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 11, 2024 | — |
| 6-K | Current report (foreign issuer) | Mar 7, 2024 | Mar 7, 2024 |
| 6-K | Current report (foreign issuer) | Jan 3, 2024 | Jan 3, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 15, 2023 | — |
| 6-K | Current report (foreign issuer) | Nov 9, 2023 | Nov 9, 2023 |
| EFFECT | Filing | Nov 3, 2023 | — |
| CORRESP | Letter to the SEC | Nov 1, 2023 | — |
| F-3/A | Filing | Oct 30, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 16, 2023 | — |
| 6-K | Current report (foreign issuer) | Aug 14, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Aug 8, 2023 | Aug 8, 2023 |
| 4 | Insider transaction | Jul 5, 2023 | Jun 14, 2023 |
| 6-K | Current report (foreign issuer) | Jul 3, 2023 | Jul 3, 2023 |
| 4 | Insider transaction | Jun 20, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 16, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2023 | Jun 14, 2023 |
| 3 | Initial insider ownership | Jun 5, 2023 | Jun 1, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 5, 2023 | Jun 1, 2023 |
| RW | Filing | Jun 2, 2023 | — |
| S-1/A | Amended registration statement | May 19, 2023 | — |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 4 | Insider transaction | Mar 23, 2023 | Mar 16, 2023 |
| 4 | Insider transaction | Mar 23, 2023 | Mar 16, 2023 |
| 4 | Insider transaction | Mar 23, 2023 | Mar 16, 2023 |
| 4 | Insider transaction | Mar 23, 2023 | Mar 16, 2023 |
| S-1/A | Amended registration statement | Mar 22, 2023 | — |
| S-1/A | Amended registration statement | Mar 21, 2023 | — |
| ARS | Annual report to shareholders | Mar 21, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| S-1/A | Amended registration statement | Feb 22, 2023 | — |
| 8-K |
Current report
Other events
|
Feb 21, 2023 | Feb 21, 2023 |
| S-1/A | Amended registration statement | Feb 21, 2023 | — |
| 8-K |
Current report
Results of operations
|
Feb 21, 2023 | Dec 31, 2022 |
| S-1 | Registration statement | Jan 13, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 11, 2023 | Jan 11, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Jan 5, 2023 | — |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 8-K |
Current report
Other events
|
Jan 3, 2023 | Jan 3, 2023 |
| 8-K/A | Amended current report | Nov 29, 2022 | Nov 14, 2022 |
| 4 | Insider transaction | Nov 18, 2022 | Nov 16, 2022 |
| 4 | Insider transaction | Nov 17, 2022 | Nov 16, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 17, 2022 | — |
| 8-K |
Current report
Other events
|
Nov 16, 2022 | Nov 16, 2022 |
| 3 | Initial insider ownership | Nov 15, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 14, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| S-8 | Employee stock plan registration | Aug 15, 2022 | — |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2022 | Aug 12, 2022 |
| 3 | Initial insider ownership | Jun 21, 2022 | Jun 16, 2022 |
| 8-K | Current report | Jun 21, 2022 | Jun 21, 2022 |
| 4 | Insider transaction | Jun 21, 2022 | Mar 16, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2022 | Jun 1, 2022 |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| 4 | Insider transaction | May 25, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 19, 2022 | May 18, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| DEF 14A | Proxy statement | Apr 28, 2022 | Apr 28, 2022 |
| 424B5 | Prospectus supplement | Apr 25, 2022 | — |
| 10-K | Annual report | Mar 30, 2022 | Dec 31, 2021 |
| 4 | Insider transaction | Mar 21, 2022 | Mar 18, 2022 |
| 4 | Insider transaction | Mar 21, 2022 | Mar 14, 2022 |
| 4 | Insider transaction | Mar 15, 2022 | Mar 14, 2022 |
| 4 | Insider transaction | Mar 15, 2022 | Mar 14, 2022 |
| 4 | Insider transaction | Mar 14, 2022 | Mar 11, 2022 |
| 4 | Insider transaction | Mar 9, 2022 | Mar 7, 2022 |
| 4 | Insider transaction | Mar 9, 2022 | Mar 7, 2022 |
| 4 | Insider transaction | Mar 9, 2022 | Mar 7, 2022 |
| 4 | Insider transaction | Mar 9, 2022 | Mar 7, 2022 |
| 4 | Insider transaction | Mar 9, 2022 | Mar 7, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2022 | Mar 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Feb 11, 2022 | Feb 11, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2022 | — |
| SC 13D | Ownership over 5% (active) | Jan 20, 2022 | — |
| DEF 14A | Proxy statement | Jan 5, 2022 | Jan 5, 2022 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2021 | Dec 23, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 16, 2021 | Dec 16, 2021 |
| 4 | Insider transaction | Dec 8, 2021 | Dec 6, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 3, 2021 | Dec 3, 2021 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Nov 12, 2021 | Nov 12, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 3 | Initial insider ownership | Nov 12, 2021 | Nov 8, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 8, 2021 | Nov 8, 2021 |
| 3 | Initial insider ownership | Nov 4, 2021 | Oct 25, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2021 | Nov 3, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Oct 26, 2021 | Oct 26, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 25, 2021 | Oct 25, 2021 |
| DEF 14A | Proxy statement | Sep 17, 2021 | Sep 17, 2021 |
| S-8 | Employee stock plan registration | Sep 13, 2021 | — |
| PRE 14A | Preliminary proxy statement | Sep 3, 2021 | Sep 3, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 2, 2021 | Sep 2, 2021 |
| 10-Q | Quarterly report | Aug 13, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2021 | Aug 13, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jul 22, 2021 | Jul 22, 2021 |
| DEF 14A | Proxy statement | Jun 14, 2021 | Jun 14, 2021 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2021 | Jun 1, 2021 |
| EFFECT | Filing | May 17, 2021 | — |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| CORRESP | Letter to the SEC | May 12, 2021 | — |
| 4 | Insider transaction | May 10, 2021 | May 7, 2021 |
| UPLOAD | Letter from the SEC | May 5, 2021 | — |
| S-3 | Shelf registration | Apr 30, 2021 | — |
| 424B3 | Prospectus | Apr 29, 2021 | — |
| EFFECT | Filing | Apr 28, 2021 | — |
| CORRESP | Letter to the SEC | Apr 26, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2021 | — |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| 4 | Insider transaction | Apr 21, 2021 | Apr 19, 2021 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 15, 2021 | — |
| S-3 | Shelf registration | Apr 15, 2021 | — |
| 8-K/A | Amended current report | Apr 14, 2021 | Mar 15, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534248
- Former names
- Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.